Speciality Medicines Ltd Share Price – BSE

Pharmaceuticals, Small Cap

The company said it has entered into a commercial arrangement with a global distributor for pharmaceutical finished products worth about $2 million, or approximately Rs 18.8 crore.

Under the agreement, the overseas partner will distribute, market and sell the company?s products, expanding its international reach.

The company said the deal is expected to strengthen its distribution network and improve revenue visibility going forward.

It added that the transaction is not a related party deal and none of the promoters have any interest in the arrangement.

Speciality Medicines is engaged in the marketing, distribution and contract manufacturing of specialty pharmaceutical formulations used in areas such as oncology, immunology, neurology and rare diseases. Its portfolio includes high-value oral and injectable therapies across multiple dosage forms.

For the period ended 31 October 2025, the company reported revenue from operations of Rs 36.72 crore and net profit of Rs 6.06 crore.

The company was listed on the BSE SME platform on 30 March 2026 at Rs 124, in line with its IPO price. The issue was subscribed 2.19 times.

The scrip was listed at Rs 124, matching the initial public offer (IPO) price. The counter hit a high of Rs 129.50 and a low of Rs 124. About 13.38 lakh shares of the company changed hands at the counter.

Speciality Medicines' IPO was subscribed 2.19 times. The issue opened for bidding on 20 March 2026 and it closed on 24 March 2026. The price band of the IPO was fixed between Rs 117 to Rs 124 per share.

The IPO comprised fresh issue of 23,50,000 equity shares. The company intends to utilise the net proceeds for setting up a research and development (R&D) centre in Valsad, Gujarat; product registration in international markets; product development for sale in international markets; funding marketing and promotional activities; meeting working capital requirements and for general corporate purposes.

Speciality Medicines is involved in the marketing, distribution, and contract manufacturing of specialty pharmaceutical formulations used to treat complex and chronic conditions across areas such as oncology, immunology, neurology, and rare diseases. The company offers a broad portfolio of high-cost oral and injectable therapies in multiple dosage forms, including tablets, injections, inhalers, and infusions. Its operations are structured around two integrated models: contract manufacturing of approved formulations for international markets and the sourcing, marketing, and distribution of specialty pharmaceutical products from other manufacturers. As of 28 February 2026, the company had a total of 18 permanent employees across various departments.

The company recorded revenue from operations of Rs 36.72 crore and net profit of Rs 6.06 crore for the period ended 31 October 2025.

Powered by Capital Market - Live News